Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: TM9SF1 expression correlates with autoimmune disease activity and regulates antibody production through mTOR-dependent autophagy

Fig. 5

Differences in cytokine expression levels in RA and SLE patients stratified according to low or high levels of TM9SF1 expression. RA patients: A FOXP3; B IFN-γ; C TNF-α; D IL-6; E IL-17A. SLE patients: F FOXP3; G IFN-γ; H TNF-α; I IL-6; J IL-17A. Median TM9SF1 expression levels, for RA patients: 0.29; for SLE patients: 0.40. RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; FOXP3, forkhead box P3; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; IL-17A, interleukin-17A. (A)-(J) were analyzed by independent-samples t tests. ***P < 0.001

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us